Cargando…
Correction to: Efficacy and safety of ixazomib plus lenalidomide and dexamethasone following injectable pi‑based therapy in relapsed/refractory multiple myeloma
| Autores principales: | , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Springer Berlin Heidelberg
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10444673/ https://www.ncbi.nlm.nih.gov/pubmed/37432416 http://dx.doi.org/10.1007/s00277-023-05355-7 |
| _version_ | 1785094001127325696 |
|---|---|
| author | Abe, Yu Sasaki, Makoto Takezako, Naoki Ito, Shigeki Suzuki, Kazuhito Handa, Hiroshi Chou, Takaaki Yoshida, Takahiro Mori, Ikuo Shinozaki, Tomohiro Suzuki, Kenshi |
| author_facet | Abe, Yu Sasaki, Makoto Takezako, Naoki Ito, Shigeki Suzuki, Kazuhito Handa, Hiroshi Chou, Takaaki Yoshida, Takahiro Mori, Ikuo Shinozaki, Tomohiro Suzuki, Kenshi |
| author_sort | Abe, Yu |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-10444673 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2023 |
| publisher | Springer Berlin Heidelberg |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-104446732023-08-24 Correction to: Efficacy and safety of ixazomib plus lenalidomide and dexamethasone following injectable pi‑based therapy in relapsed/refractory multiple myeloma Abe, Yu Sasaki, Makoto Takezako, Naoki Ito, Shigeki Suzuki, Kazuhito Handa, Hiroshi Chou, Takaaki Yoshida, Takahiro Mori, Ikuo Shinozaki, Tomohiro Suzuki, Kenshi Ann Hematol Correction Springer Berlin Heidelberg 2023-07-11 2023 /pmc/articles/PMC10444673/ /pubmed/37432416 http://dx.doi.org/10.1007/s00277-023-05355-7 Text en © Springer-Verlag GmbH Germany, part of Springer Nature 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
| spellingShingle | Correction Abe, Yu Sasaki, Makoto Takezako, Naoki Ito, Shigeki Suzuki, Kazuhito Handa, Hiroshi Chou, Takaaki Yoshida, Takahiro Mori, Ikuo Shinozaki, Tomohiro Suzuki, Kenshi Correction to: Efficacy and safety of ixazomib plus lenalidomide and dexamethasone following injectable pi‑based therapy in relapsed/refractory multiple myeloma |
| title | Correction to: Efficacy and safety of ixazomib plus lenalidomide and dexamethasone following injectable pi‑based therapy in relapsed/refractory multiple myeloma |
| title_full | Correction to: Efficacy and safety of ixazomib plus lenalidomide and dexamethasone following injectable pi‑based therapy in relapsed/refractory multiple myeloma |
| title_fullStr | Correction to: Efficacy and safety of ixazomib plus lenalidomide and dexamethasone following injectable pi‑based therapy in relapsed/refractory multiple myeloma |
| title_full_unstemmed | Correction to: Efficacy and safety of ixazomib plus lenalidomide and dexamethasone following injectable pi‑based therapy in relapsed/refractory multiple myeloma |
| title_short | Correction to: Efficacy and safety of ixazomib plus lenalidomide and dexamethasone following injectable pi‑based therapy in relapsed/refractory multiple myeloma |
| title_sort | correction to: efficacy and safety of ixazomib plus lenalidomide and dexamethasone following injectable pi‑based therapy in relapsed/refractory multiple myeloma |
| topic | Correction |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10444673/ https://www.ncbi.nlm.nih.gov/pubmed/37432416 http://dx.doi.org/10.1007/s00277-023-05355-7 |
| work_keys_str_mv | AT abeyu correctiontoefficacyandsafetyofixazomibpluslenalidomideanddexamethasonefollowinginjectablepibasedtherapyinrelapsedrefractorymultiplemyeloma AT sasakimakoto correctiontoefficacyandsafetyofixazomibpluslenalidomideanddexamethasonefollowinginjectablepibasedtherapyinrelapsedrefractorymultiplemyeloma AT takezakonaoki correctiontoefficacyandsafetyofixazomibpluslenalidomideanddexamethasonefollowinginjectablepibasedtherapyinrelapsedrefractorymultiplemyeloma AT itoshigeki correctiontoefficacyandsafetyofixazomibpluslenalidomideanddexamethasonefollowinginjectablepibasedtherapyinrelapsedrefractorymultiplemyeloma AT suzukikazuhito correctiontoefficacyandsafetyofixazomibpluslenalidomideanddexamethasonefollowinginjectablepibasedtherapyinrelapsedrefractorymultiplemyeloma AT handahiroshi correctiontoefficacyandsafetyofixazomibpluslenalidomideanddexamethasonefollowinginjectablepibasedtherapyinrelapsedrefractorymultiplemyeloma AT choutakaaki correctiontoefficacyandsafetyofixazomibpluslenalidomideanddexamethasonefollowinginjectablepibasedtherapyinrelapsedrefractorymultiplemyeloma AT yoshidatakahiro correctiontoefficacyandsafetyofixazomibpluslenalidomideanddexamethasonefollowinginjectablepibasedtherapyinrelapsedrefractorymultiplemyeloma AT moriikuo correctiontoefficacyandsafetyofixazomibpluslenalidomideanddexamethasonefollowinginjectablepibasedtherapyinrelapsedrefractorymultiplemyeloma AT shinozakitomohiro correctiontoefficacyandsafetyofixazomibpluslenalidomideanddexamethasonefollowinginjectablepibasedtherapyinrelapsedrefractorymultiplemyeloma AT suzukikenshi correctiontoefficacyandsafetyofixazomibpluslenalidomideanddexamethasonefollowinginjectablepibasedtherapyinrelapsedrefractorymultiplemyeloma |